Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 17/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | TACR2 | P21452 | 7/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896249 | 1.00 | TACR3 (0.63) | TACR3CYP2C9TACR2TRPV4OPRM1 | |
| SCHEMBL4887323 | 0.92 | TACR3 (0.67) | TACR3CYP2C9TACR2TRPV4 | |
| SCHEMBL4887319 | 0.92 | TACR3 (0.67) | TACR3CYP2C9TACR2TRPV4 | |
| SCHEMBL4893103 | 0.92 | TACR3 (0.67) | TACR3CYP2C9TRPV4 | |
| SCHEMBL4893095 | 0.92 | TACR3 (0.67) | TACR3CYP2C9TRPV4 | |
| SCHEMBL4898679 | 0.90 | TACR3 (0.68) | TACR3CYP2C9TRPV4 | |
| SCHEMBL4898683 | 0.90 | TACR3 (0.68) | TACR3CYP2C9TRPV4 | |
| SCHEMBL5635725 | 0.85 | TACR3 (0.74) | TACR3CYP2C9TACR2OPRM1 | |
| SCHEMBL4884299 | 0.81 | DHODH (0.50) | TACR3TACR2OPRM1 | |
| SCHEMBL4893649 | 0.79 | TACR2 (0.52) | TACR3TACR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | claimed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | TACR1, TACR2, KCNA3 | TACR3 10/4885CYP2C9 1311/4885TACR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.